Literature DB >> 28500365

Capsule, septum, and T2 hyperintense foci for differentiation between large hepatocellular carcinoma (≥5 cm) and intrahepatic cholangiocarcinoma on gadoxetic acid MRI.

Jiyoung Hwang1, Young Kon Kim2, Ji Hye Min3, Seo-Youn Choi4, Woo Kyung Jeong3, Seong Sook Hong1, Hyun-Joo Kim1, Soohyun Ahn5, Hyeon Seon Ahn5.   

Abstract

OBJECTIVE: To determine the added value of capsule, septum, and T2 hyperintense foci for differentiating large hepatocellular carcinoma (HCC; ≥ 5 cm) from intrahepatic cholangiocarcinoma (ICC) using gadoxetic acid MRI.
METHODS: The study included 116 patients (94 men, 22 women; mean age, 56.8 years) with surgically confirmed HCCs (n = 87, 5.0-18.0 cm) or ICCs (n = 29, 5.0-14.0 cm) who underwent gadoxetic acid MRI. Three observers independently reviewed MRIs in two sessions, examining enhancement patterns only and then adding capsule, septum, and T2 hyperintense foci. Reviewers used a five-point scale to score accuracy, sensitivity, and specificity.
RESULTS: A significant increase was observed in accuracy when ancillary features (96.1-98.3%) were added compared to enhancement pattern only (83.6-88.4%; p ≤ 0.02). Sensitivity was significantly increased with combined reading (97.1-98.3%) compared to enhancement features only (81.6-88.5%; p ≤ 0.006) for two observers, with no difference in specificity (84.5-89.7% vs. 86.2-98.3%; p > 0.05). We found substantial to excellent interobserver agreement for ancillary features (0.598-0.976).
CONCLUSION: Adding capsule, septum, and T2 hyperintense foci to enhancement patterns for gadoxetic acid MRI increased diagnostic performance for characterizing large HCC by differentiating it from ICC. KEY POINTS: • Capsule, septum, and T2 hyperintense foci were useful for characterizing large HCC. • Adding ancillary features to enhancement pattern increased accuracy for diagnosing large HCC. • Interobserver agreement was substantial to excellent for ancillary features.

Entities:  

Keywords:  Ancillary feature; Cholangiocarcinoma; Gadoxetic acid; Hepatocellular carcinoma; MRI

Mesh:

Substances:

Year:  2017        PMID: 28500365     DOI: 10.1007/s00330-017-4846-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  34 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI.

Authors:  Y S Chong; Y K Kim; M W Lee; S H Kim; W J Lee; H C Rhim; S J Lee
Journal:  Clin Radiol       Date:  2012-03-15       Impact factor: 2.350

3.  Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee; Sang Min Lee; Jeong Sub Lee; Jin Young Park; Joon Koo Han
Journal:  J Magn Reson Imaging       Date:  2016-04-18       Impact factor: 4.813

4.  Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.

Authors:  Young Joo Suh; Myeong-Jin Kim; Jin-Young Choi; Young Nyun Park; Mi-Suk Park; Ki Whang Kim
Journal:  AJR Am J Roentgenol       Date:  2011-07       Impact factor: 3.959

5.  Clinical significance of the transitional phase at gadoxetate disodium-enhanced hepatic MRI for the diagnosis of hepatocellular carcinoma: preliminary results.

Authors:  Yuko Nakamura; Naoyuki Toyota; Shuji Date; Seitaro Oda; Tomohiro Namimoto; Yasuyuki Yamashita; Toru Beppu; Kazuo Awai
Journal:  J Comput Assist Tomogr       Date:  2011 Nov-Dec       Impact factor: 1.826

6.  Triple-phase MDCT of hepatocellular carcinoma.

Authors:  K H Y Lee; M E O'Malley; M A Haider; A Hanbidge
Journal:  AJR Am J Roentgenol       Date:  2004-03       Impact factor: 3.959

7.  Clinicopathological study of hepatocellular carcinoma with peliotic change.

Authors:  Masaru Fujimoto; Osamu Nakashima; Mina Komuta; Toshimitsu Miyaaki; Masamichi Kojiro; Hirohisa Yano
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

8.  Peripheral mass-forming cholangiocarcinoma in cirrhotic liver.

Authors:  Su Jin Kim; Jeong Min Lee; Joon Koo Han; Ki Hyun Kim; Jae Young Lee; Byung Ihn Choi
Journal:  AJR Am J Roentgenol       Date:  2007-12       Impact factor: 3.959

9.  ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.

Authors:  E Neri; M A Bali; A Ba-Ssalamah; P Boraschi; G Brancatelli; F Caseiro Alves; L Grazioli; T Helmberger; J M Lee; R Manfredi; L Martì-Bonmatì; C Matos; E M Merkle; B Op De Beeck; W Schima; S Skehan; V Vilgrain; C Zech; C Bartolozzi
Journal:  Eur Radiol       Date:  2015-07-21       Impact factor: 5.315

10.  Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging.

Authors:  Elmar M Merkle; Christoph J Zech; Carlo Bartolozzi; Mustafa R Bashir; Ahmed Ba-Ssalamah; Alexander Huppertz; Jeong Min Lee; Jens Ricke; Michiie Sakamoto; Claude B Sirlin; Sheng-Long Ye; Mengsu Zeng
Journal:  Eur Radiol       Date:  2015-06-13       Impact factor: 5.315

View more
  9 in total

1.  Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

Authors:  Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu Yamamoto
Journal:  Liver Cancer       Date:  2022-02-23       Impact factor: 12.430

2.  Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI.

Authors:  Xinai Liu; Xiaoyan Ni; Yubo Li; Chun Yang; Yi Wang; Chunzheng Ma; Changwu Zhou; Xin Lu
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

3.  Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging.

Authors:  Seo-Youn Choi; Young Kon Kim; Ji Hye Min; Tae Wook Kang; Woo Kyoung Jeong; Soohyun Ahn; Hojeong Won
Journal:  Eur Radiol       Date:  2018-01-15       Impact factor: 5.315

Review 4.  Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging.

Authors:  Jae Hyun Kim; Ijin Joo; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

5.  Liver Imaging and Data System (LI-RADS) Version 2018 and Other Imaging Features in Intrahepatic Cholangiocarcinoma in Chinese Adults with vs. without Chronic Hepatitis B Viral Infection.

Authors:  Ying-Ying Liang; Shuo Shao; Sichi Kuang; Jingbiao Chen; Jing Zhou; Bingjun He; Linqi Zhang; Yao Zhang; Kathryn J Fowler; Jin Wang
Journal:  Can J Gastroenterol Hepatol       Date:  2021-03-04

Review 6.  Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI.

Authors:  Jelena Djokic Kovač; Aleksandra Janković; Aleksandra Đikić-Rom; Nikica Grubor; Andrija Antić; Vladimir Dugalić
Journal:  Curr Oncol       Date:  2022-01-30       Impact factor: 3.677

Review 7.  Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers.

Authors:  Yeun-Yoon Kim; Mi-Suk Park; Khalid Suliman Aljoqiman; Jin-Young Choi; Myeong-Jin Kim
Journal:  Clin Mol Hepatol       Date:  2019-01-21

8.  Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.

Authors:  Christoph J Zech; Ahmed Ba-Ssalamah; Thomas Berg; Hersh Chandarana; Gar-Yang Chau; Luigi Grazioli; Myeong-Jin Kim; Jeong Min Lee; Elmar M Merkle; Takamichi Murakami; Jens Ricke; Claude B Sirlin; Bin Song; Bachir Taouli; Kengo Yoshimitsu; Dow-Mu Koh
Journal:  Eur Radiol       Date:  2019-08-05       Impact factor: 5.315

9.  Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.

Authors:  Lang Chen; Furong Zeng; Lei Yao; Tongdi Fang; Mengting Liao; Jing Long; Liang Xiao; Guangtong Deng
Journal:  Cancer Med       Date:  2020-01-05       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.